Sign in
Taking people in United StatesPhase 1/2

Donor Stem Cell Transplant Tested in Severe Sickle Cell and Other Anemias

Tests a donor stem cell transplant in people with severe sickle cell disease.

Key facts

Who runs it
Paul Szabolcs
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Status
Recruiting
Phase
Phase 1/2
People taking part
5 people, planned
Started
2 Aug 2018
Expected to end
1 Aug 2028
Type of study
Interventional
Treatments tested
  • CD3/CD19 depleted leukocytes
  • CD45RA depleted leukocytes
  • Hydroxyurea
  • Rituximab
  • Alemtuzumab
  • Fludarabine
  • Thiotepa
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults with severe sickle cell disease, beta-thalassemia or Diamond-Blackfan anemia who need a stem cell transplant from a partly matched donor.

Age
5 Years to 40 Years
Sex
All sexes
Disease stage
Sickle cell disease (Hemoglobin SS or Sβ0-thalassemia) with complications such as repeated painful episodes, repeated acute chest syndrome, stroke, or regular blood transfusions. Or beta-thalassemia or Diamond-Blackfan anemia that depends on transfusions with iron overload.
Earlier treatment
People with sickle cell disease must have tried hydroxyurea and it must have failed. A search for a fully matched unrelated donor must have found none. No stem cell transplant in the 6 months before conditioning.
Biomarker or test result
Donor with a minimum HLA match of 4/8 for a related donor or 6/8 for an unrelated donor. HIV negative by PCR. Negative pregnancy test for females 10 years or older or who have reached menarche, unless surgically sterilized.

Main reasons for not taking part

  • Has a better donor option, such as a matched sibling or matched unrelated donor
  • Stem cell transplant in the 6 months before conditioning
  • Central nervous system event in the 6 months before conditioning
  • Pregnant or breastfeeding
  • Uncontrolled bacterial, viral or fungal infection

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patient, parent, or legal guardian must have given written informed consent and/or assent according to FDA guidelines
  • Ages 5 years to 40 years, at time of consent
  • Diagnosis of Sickle Cell Disease (Hemoglobin SS, Sβ0-thalassemia) complicated by any of the following:; Recurrent acute painful episodes (also known as vaso-occlusive crises; VOC) despite supportive care, minimum of 2 new pain events per year requiring hospitalization for parenteral pain management in the previous 2 years; Recurrent acute chest syndrome (ACS) despite supportive care, minimum of 2 episodes in preceding 2-year period; Stroke or neurologic event lasting > 24 hours with an accompanying infarct on MRI in any patient for all ages; Brain MRI with silent infarct without clinical event in patients ≤ 16 years; Chronic transfusion therapy defined as > 8 packed red blood cell transfusions per year in the year prior to enrollment and/or evidence of red blood cell alloimmunization; Elevated transcranial Doppler velocities - > 200 cm/s, via the non-imaging technique or > 185 cm/s by the imaging technique measured on 2 separate occasions ≥ 1-month apart; Elevated TRV > 2.6m/s in patients ≥ 16 years old; Sickle-related renal insufficiency and/or sickle hepatopathy and/or any irreversible end-organ damage in patients ≥ 16 years old; OR Diagnosis of beta-thalassemia or Diamond-Blackfan anemia complicated by transfusion dependence with evidence of iron overload
  • A minimum donor match of 4/8 via high resolution HLA typing at HLA-A, -B, -C, -DRB1 loci in the related setting or minimum donor match of 6/8 via high resolution HLA typing at HLA-A, -B, -C, -DRB1 loci (with the DRB1 locus as a full match requirement). An unrelated donor and cord blood search must have been completed without an eligible 8/8 matched unrelated donor or 6/8 cord blood unit available. Patients who may have acceptable cord blood donor options (4/6 or better) but are limited by cell dose of a single cord will also be eligible for the proposed study
  • Adequate function of other organ systems as measured by:; Creatinine clearance or GFR ≥ 45 ml/min/1.73m; Hepatic transaminases (ALT/AST) ≤ 3 x upper limit of normal; Liver MR imaging for iron content should be performed in all patients with Ferritin > 500 ng/mL. If hepatic iron content > 10mg Fe/g liver should have hepatology consultation and liver biopsy to confirm absence of cirrhosis, fibrosis or hepatitis; Adequate cardiac function as measure by echocardiogram (shortening fraction > 26% or ejection fraction > 40% or >80% of age-specific normal); Pulmonary evaluation testing demonstrating FEV1/FVC ≥ 60% of predicted for age and/or resting pulse oximeter ≥ 92% on room air; Cardiology clearance to proceed with conditioning regimen and HSCT; Pulmonology clearance to proceed with conditioning regimen and HSCT
  • Subjects must be human immunodeficiency virus (HIV) negative by PCR
  • Negative pregnancy test for females ≥10 years old or who have reached menarche, unless surgically sterilized
  • All females of childbearing potential and sexually active males must agree to use an FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause a birth defect
  • Subject and/or parent guardian will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting (Refer to section,
  • Hydroxyurea must have been trialed and failed in patients with sickle cell disease; Patient Exclusion Criteria
  • Patients with alternate, superior donor options (matched sibling donor or matched unrelated donor)
  • Patients who have undergone stem cell transplantation in the 6 months prior to anticipated conditioning
  • Patients with history of a central nervous system (CNS) event within six months prior to start of conditioning (patient will be delayed until eligible)
  • Patients who are pregnant or lactating
  • Patients with uncontrolled bacterial, viral or fungal infection
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 5 and 40 years old?

Where in United States

  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Paul Pszabolcs, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidentical related donor stem cells, this study will increase the number of patients who can undergo a stem cell transplant for their specified disease. Additionally, using a T-cell depleted approach should reduce the incidence of graft-versus-host disease which would otherwise be increased in a mismatched transplant setting.

The group in the trial

  • Hematopoietic Stem Cell TransplantationTreatment being tested

    All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost. Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy.

    Treatment: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, and Thiotepa

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias
Plain-language title
Donor Stem Cell Transplant Tested in Severe Sickle Cell and Other AnemiasGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03653338, who can take part
Record updated
13 August 2026